Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg

DRUG2 trials

Sponsors

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA, Philipps University Marburg

Conditions

Hypertension, PulmonaryPulmonary Arterial Hypertension (PAH)

Phase 2

A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

CompletedNCT04945460

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAHypertension, Pulmonary

Start: 2021-12-29End: 2026-04-09Updated: 2026-04-15

SIRIUS - Initial Combination Therapy With an Endothelin Receptor Antagonist, a Phosphodiesterase-5 Inhibitor and Sotatercept in Patients With Newly Diagnosed Pulmonary Arterial Hypertension

Not yet recruitingNCT07266519

Philipps University MarburgPulmonary Arterial Hypertension (PAH)

Start: 2026-07-01End: 2028-10-31Target: 25Updated: 2025-12-05